Gilead to Acquire PepStar Oral IL-23R Program for $1.275 Billion
Gilead agreed to acquire the program from privately held PepStar Therapeutics for $1.275 billion in cash, gaining worldwide rights to its lead asset, HCXT-2001.
Gilead Sciences agreed to buy privately held PepStar Therapeutics’ oral IL-23R inhibitor program for $1.275 billion in cash. The transaction grants Gilead worldwide rights to the program, including its lead asset, HCXT-2001. Gilead plans to develop the asset alone or in…